ATTR Amyloidosis Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

ATTR Amyloidosis Treatment Market is segmented By Type (Hereditary ATTR Amyloidosis, Wild-type ATTR Amyloidosis), By Treatment (Pharmacological Therapies, Organ Transplantation, Supportive Care), By Route of Administration(Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

ATTR Amyloidosis Treatment Market is segmented By Type (Hereditary ATTR Amyloidosis, Wild-type ATTR Amyloidosis), By Treatment (Pharmacological Therap....

ATTR Amyloidosis Treatment Market Size

Market Size in USD

CAGR8.7%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	8.7%
Market Concentration	High
Major Players	Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Akcea Therapeutics, Inc.

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

ATTR Amyloidosis Treatment Market Analysis

The ATTR amyloidosis treatment market is estimated to be valued at USD 3.8 Bn in 2024 and is expected to reach USD 6.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031. ATTR amyloidosis is a rare genetic disease with deposition of abnormal protein called amyloid in organs and tissues. Several treatment options and novel drug pipeline is expected to drive the growth of this market during the forecast period.

ATTR Amyloidosis Treatment Market Report Snapshots

Buy Now